Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Canc… (NCT07198672) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag
45 participantsStarted 2025-10-31
Plain-language summary
Ado-trastuzumab emtansine (T-DM1) demonstrates favorable efficacy in breast cancer treatment but is frequently associated with thrombocytopenia. Multiple studies indicate that Asian populations face a higher risk of developing thrombocytopenia during T-DM1 therapy, with incidence rates ranging from 52.5% to 69.8% and ≥Grade 3 rates between 29.8% and 45.0%. Severe thrombocytopenia not only increases bleeding risks but may also necessitate T-DM1 dose delays or reductions, thereby compromising treatment efficacy and diminishing patient survival and quality of life. Herombopag selectively binds to the transmembrane region of TPO-R, activating TPO-R-dependent STAT and MAPK signaling pathways. This effectively stimulates megakaryocyte proliferation and differentiation, promoting thrombopoiesis. However, high-level evidence supporting the use of Herombopag for primary prevention of T-DM1-induced thrombocytopenia in breast cancer remains lacking.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Female, age ≥18 years;
✓. Histopathologically or cytologically confirmed diagnosis of breast cancer;
✓. Tumor tissue confirmed as HER2-positive, defined as immunohistochemistry (IHC) showing +++, or IHC++ with fluorescence in situ hybridization (FISH) demonstrating HER2-positive status;
✓. Planned to receive T-DM1 regimen based on clinical judgment;
✓. ECOG PS score: 0-2;
✓. Expected survival greater than 12 weeks;
✓. Adequate organ and bone marrow function.
Exclusion criteria
✕. A confirmed history of severe allergic reactions to the active ingredients or excipients of the therapeutic drug;
✕. Presence of other underlying diseases or comorbidities causing thrombocytopenia, such as aplastic anemia, immune thrombocytopenia, myelodysplastic syndrome, etc.;
. Individuals with hereditary bleeding disorders, coagulation dysfunction, high bleeding risk, or a history of thrombotic events (e.g., transient ischemic attack, cerebral hemorrhage, cerebral infarction, pulmonary embolism) within 6 months prior to initial medication use;
✕. Individuals with uncontrolled hypertension and a history of hypertensive crisis or hypertensive encephalopathy;
✕. Pregnant or lactating women;
✕. Presence of multiple factors affecting oral drug absorption, such as dysphagia, nausea/vomiting, chronic diarrhea, or intestinal obstruction;
✕. History of severe psychiatric disorders, substance abuse, alcoholism, or drug addiction;
✕. Currently participating in interventional clinical research treatment, or having received other investigational drugs or devices within 4 weeks prior to first dosing (individuals who failed screening for other clinical trials may be included in this study);